Figure 2.
Arithmetic mean (±SD) serum olaratumab concentration‐time profiles in Cycle 1 (A) and Cycle 3 (B) after administration of olaratumab on Days 1 and 8. Patients in Cohorts 1 and 2 received olaratumab 15 mg/kg on Days 1 and 8 of each 21‐day cycle; patients in Cohort 3 received olaratumab 20 mg/kg on Days 1 and Day 8 of Cycle 1, and 15 mg/kg on Days 1 and 8 of subsequent cycles. Patients in Cohort 1 received doxorubicin 25 mg/m2 on Days 1, 2 and 3 of each 21‐day cycle; patients in Cohorts 2 and 3 received doxorubicin 75 mg/m2 on Day 1. C min1, minimum serum concentration after the first dose